Adaptimmune Therapeutics (ADAP) has a market capitalization of $70.3M, based on 264.99M shares at a price of $0.27 (down 5.3% on Friday).
| DATE | CLOSE | VOLUME | OUTSTANDING | MARKET CAP |
|---|---|---|---|---|
April 2025 | $0.27 | 33,137,933 | 264,988,014 | $70,301,320.11 |
March 2025 | $0.20 | 51,368,820 | 252,301,800 | $49,703,454.60 |
February 2025 | $0.54 | 17,343,129 | 252,301,800 | $136,242,972.00 |
January 2025 | $0.59 | 24,199,014 | 252,301,800 | $148,858,062.00 |
December 2024 | $0.54 | 57,866,553 | 252,301,800 | $135,914,979.66 |
November 2024 | $0.72 | 46,339,163 | 252,301,800 | $181,833,907.26 |
October 2024 | $0.73 | 26,777,465 | 252,301,800 | $183,070,186.08 |
September 2024 | $0.95 | 20,620,861 | 255,769,000 | $243,082,857.60 |
August 2024 | $1.27 | 51,015,120 | 255,769,000 | $324,826,630.00 |
July 2024 | $1.33 | 41,495,831 | 255,769,000 | $340,172,770.00 |
June 2024 | $0.97 | 31,396,153 | 259,864,000 | $253,341,413.60 |
May 2024 | $1.13 | 36,469,979 | 259,864,000 | $293,646,320.00 |
April 2024 | $1.19 | 28,066,601 | 259,864,000 | $309,238,160.00 |
March 2024 | $1.58 | 39,503,910 | 241,873,600 | $382,160,288.00 |
February 2024 | $1.57 | 37,460,719 | 241,873,600 | $379,741,552.00 |
January 2024 | $0.96 | 38,324,179 | 241,873,600 | $232,198,656.00 |
December 2023 | $0.79 | 16,576,043 | 227,112,100 | $180,099,895.30 |
November 2023 | $0.50 | 8,604,689 | 227,112,100 | $113,556,050.00 |
October 2023 | $0.54 | 9,287,675 | 227,112,100 | $122,799,512.47 |
September 2023 | $0.78 | 8,654,722 | 226,308,300 | $176,520,474.00 |
August 2023 | $0.78 | 10,106,881 | 226,308,300 | $176,565,735.66 |
July 2023 | $0.94 | 13,794,758 | 226,308,300 | $213,205,049.43 |
June 2023 | $0.93 | 26,582,105 | 184,694,500 | $170,842,412.50 |
May 2023 | $1.02 | 17,108,221 | 184,694,500 | $188,388,390.00 |
April 2023 | $1.42 | 15,850,291 | 184,694,500 | $262,266,190.00 |
